Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 6/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | GRB2 | P62993 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14673292 | 0.92 | CAPN1 (0.60) | CAPN1CTSBOPRM1OPRD1OPRK1 | |
| SCHEMBL14673291 | 0.92 | CAPN1 (0.60) | CAPN1CTSBOPRM1OPRD1OPRK1 | |
| SCHEMBL20477645 | 0.92 | CAPN1 (0.60) | CAPN1CTSBOPRM1OPRD1OPRK1 | |
| SCHEMBL14728337 | 0.89 | CAPN1 (0.55) | CAPN1CTSBOPRM1OPRD1OPRK1 | |
| SCHEMBL15576934 | 0.89 | CAPN1 (0.55) | CAPN1CTSBOPRM1OPRD1OPRK1 | |
| SCHEMBL14682287 | 0.86 | CAPN1 (0.54) | CAPN1CTSBOPRM1OPRD1OPRK1 | |
| SCHEMBL21549054 | 0.86 | CAPN1 (0.54) | CAPN1CTSBOPRM1OPRD1OPRK1 | |
| SCHEMBL14673120 | 0.84 | CAPN1 (0.65) | CAPN1CTSBOPRM1OPRD1OPRK1 | |
| SCHEMBL14673121 | 0.84 | CAPN1 (0.65) | CAPN1CTSBOPRM1OPRD1OPRK1 | |
| SCHEMBL14682286 | 0.84 | CAPN1 (0.58) | CAPN1CTSBOPRM1GRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2016-12-22 | — | — | US | disclosed |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY | 2015-11-05 | — | — | US | disclosed |
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2015-02-19 | — | — | US | disclosed |
| US-8673843-B2 | NMDA receptors modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CAPN1 866/4885CTSB 4049/4885OPRM1 27/4885 |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CAPN1 866/4885CTSB 4049/4885OPRM1 27/4885 |
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CAPN1 866/4885CTSB 4049/4885OPRM1 27/4885 |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CAPN1 902/4885CTSB 4087/4885OPRM1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.